Company Profile
Reviva Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- RVPH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.48 USD (+6.12%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, RVPH closed up 6.12% at $0.4775. No new same-company headline was identified in the current news window.
Company overview
Late-Stage CNS Company
Reviva Pharmaceuticals develops internally discovered therapies for central nervous system, inflammatory, and cardiometabolic diseases.
Brilaroxazine
Brilaroxazine is the lead asset and is being advanced for schizophrenia. The compound has a broad serotonin and dopamine receptor profile intended to address positive, negative, mood, and cognitive symptoms.
Lifecycle and Regulatory Strategy
Reviva has developed a new form of brilaroxazine intended to extend patent protection and plans to incorporate it into the RECOVER-2 registrational study and a future NDA.
Future catalysts
FDA feedback on use of the new brilaroxazine form in RECOVER-2 and the future NDA is expected in mid-2026.
Enrollment in the registrational Phase 3 RECOVER-2 schizophrenia trial is expected to begin in the third quarter of 2026.
Recent news
- 01
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
Source: Reviva Pharmaceuticals
- 02
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
Source: Reviva Pharmaceuticals
- 03
- 04
Reviva Announces Letter to Shareholders
Source: Reviva Pharmaceuticals
- 05
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
Source: Reviva Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Reviva Pharmaceuticals (RVPH)?
Reviva Pharmaceuticals (RVPH) most recently closed at 0.48 USD, a +6.12% move versus the previous session.
What does Reviva Pharmaceuticals do?
Late-Stage CNS Company Reviva Pharmaceuticals develops internally discovered therapies for central nervous system, inflammatory, and cardiometabolic diseases. Brilaroxazine Brilaroxazine is the lead asset and is being advanced for schizophrenia. The compound has a broad serotonin and dopamine receptor profile intended to address positive, negative, mood,...
On which exchange is RVPH stock listed?
Reviva Pharmaceuticals (RVPH) is associated with NASDAQ, United States, Biopharma.
What is RECOVER-2?
FDA feedback on use of the new brilaroxazine form in RECOVER-2 and the future NDA is expected in mid-2026.
Which conditions is Reviva Pharmaceuticals targeting with RECOVER-2?
Reviva Pharmaceuticals is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Reviva Pharmaceuticals describe recent progress with RECOVER-2?
FDA feedback on use of the new brilaroxazine form in RECOVER-2 and the future NDA is expected in mid-2026.
What is Late-Stage?
Late-Stage CNS Company Reviva Pharmaceuticals develops internally discovered therapies for central nervous system, inflammatory, and cardiometabolic diseases.
What should investors watch for with Late-Stage?
FDA feedback on use of the new brilaroxazine form in RECOVER-2 and the future NDA is expected in mid-2026. Enrollment in the registrational Phase 3 RECOVER-2 schizophrenia trial is expected to begin in the third quarter of 2026.